Patients using GLP-1 weight-loss medications such as Wegovy and Mounjaro face significant risks of regaining lost weight once they discontinue treatment, potentially creating a new cycle of yo-yo dieting.
The phenomenon underscores that long-term medical supervision may be as crucial to the success of these therapies as the drugs themselves.
This dynamic has direct implications for the commercial trajectories of Novo Nordisk and Eli Lilly, the primary manufacturers of semaglutide and tirzepatide respectively.
If weight regain is common and rapid upon cessation, the total addressable market for these chronic-use therapies could expand, but so too could the pressure on healthcare systems to manage long-term dependency and side effects.
The broader economic impact extends beyond pharmaceuticals.
Previous analysis has highlighted how the surge in GLP-1 demand is already reshaping consumer spending patterns, particularly in the apparel sector across the UK and US.